Regulation Of Cardiometabolic Disease By A Novel ATP Binding Cholesterol Transporter, ABCA8: A New Therapeutic Target?
Funder
National Health and Medical Research Council
Funding Amount
$316,585.00
Summary
Approximately 1.7 million Australians and 12% of the population in Singapore has type 2 diabetes (T2D). We have identified a cholesterol transporter, ABCA8, the absence of which produces symptoms similar to those seen in humans with T2D. The aim of this project is to understand the molecular basis of the diabetes symptoms in mice that do not have ABCA8 with a view to identifying this transporter as a drug target to reduce T2D and its complications, including heart attacks.
Biomarkers For Risk And Outcomes Of Type 2 Diabetes: A Discovery And Validation Approach In Australian And Chinese Subjects
Funder
National Health and Medical Research Council
Funding Amount
$599,489.00
Summary
The aim is to make better outcomes for people with Type 2 diabetes in Australia and China, by exploring various tests to improve prediction of diabetes progression, complication risk and treatment response. The team has data and samples from the Fenofibrate Intervention and Event Lowering in Diabetes Trial and from the Shanghai Diabetes Study. This approach is very time and cost-effective. We will also study animal models to understand mechanisms of diabetes damage, and test new treatments.
Application Of New Technologies And Methods In Nutrition Research – The Example Of Phenotypic Flexibility
Funder
National Health and Medical Research Council
Funding Amount
$210,823.00
Summary
The aim of the Nutritech project is to develop better diagnostics of the effect of foods and dietary supplements on the health of an individual. NutriTech will develop new analytical technologies to comprehensively investigate the diet-health interrelationship and critically assess their usefulness for the future of nutrition research. A new automated method for measuring the effect of diet on multiple measures of DNA damage and nutrients in single cells will be developed at CSIRO.
Bacterial Metabolite Mediated Regulation Of The Immune And Metabolic Systems
Funder
National Health and Medical Research Council
Funding Amount
$303,374.00
Summary
The cellular and molecular events that underpin metabolic syndrome diseases, such as diabetes, fatty liver, etc are poorly understood. However recent advances provide new clues. First, the immune system is intimately connected to metabolism. Second, the gut microbiota, and its metabolites such as acetate and butyrate are also important. These metabolites induce epigenetic changes in cells. We will study how metabolites induce molecular changes epigenetically, and how this controls metabolism.
Anti-inflammatory Copper Complexes For Treatment Of Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$603,622.00
Summary
Brain inflammation and disrupted metabolism of the biologically important metal, copper, play key roles in Alzheimer’s disease (AD) progression. Our team has developed new copper-based therapeutics, but limited knowledge of how they work impedes clinical trials. My recent findings indicate that these drugs potently prevent inflammation. My proposal seeks to understand how copper-complexes reduce damaging inflammatory responses in novel human cell models of AD.
Identifying Novel Lipid And Genetic Signatures Of Metabolic Disease In Early Childhood
Funder
National Health and Medical Research Council
Funding Amount
$354,592.00
Summary
Both our genetic makeup and environment can contribute to the development of obesity, diabetes and heart disease. Although onset usually occurs in adulthood, the progression towards disease can start in early life. Early childhood represents an opportunity for intervention to avoid adverse health outcomes in adulthood. This proposal combines two established birth cohorts from Singapore (GUSTO) and Australia (BIS) to examine the genetic and environmental origins of metabolic diseases.
Role Of Sphingolipid Signalling In Hepatic Insulin Resistance And Its Application In Prediction Of Risk For Type 2 Diabetes And Prediabetes
Funder
National Health and Medical Research Council
Funding Amount
$563,305.00
Summary
Type 2 diabetes is expected to reach epidemic proportions in the coming decades. Prediabetes is usually unrecognized and constitutes a major public health concern that needs earlier interventions, because the majority of prediabetic subjects proceed to T2D. We have identified an enzyme that plays an important role in insulin signalling. The possibility is that the level or activity of this enzyme is a potential biomarker of the prediabetes state and could be also used as a target